Mark R. Windt, M.D.

Academic Appointments:

---

Awards and Honors:

• Breathe New Hampshire Honors Mark R. Windt, M.D. with this year’s prestigious Robert B. Kerr Award for his many years of contribution to furthering lung health in the Granite State, 2012.
• Grass Foundation Fellowship, Cornell University, 1973.
• Immunology Research Grant, Memorial-Sloan-Kettering Hospital. Third year of medical school 1976 and 1977.
• Schering Fellowship Award in Allergy and Immunology 1982.
• President, New Hampshire-Vermont Thoracic Society, 1995-1997.
• President, Rockingham County Medical Society, NH 1994-present.
• President, Medical Staff Exeter Hospital, NH 2000-2002
• National Registry of Who’s Who, 1999.
• Board of Directors, Asthma and Allergy Foundation of America, New England Chapter (Current).
• Board of Directors, American Lung Association of New Hampshire, 1989-2007.
• Board of Directors, Breathe New Hampshire, 2007-2011.
• Vice Chairman, Board of Directors, American Lung Association of New Hampshire, 1999-2001.
• Chairman, Board of Directors, American Lung Association of New Hampshire, 2001-2003.
• Board of Directors, New Hampshire Symphony Orchestra, 2004-2006.
• CCR representative NH and VT. American Thoracic Society.
• American Thoracic Society, Environmental Health Policy Committee.(Current)
• American Thoracic Society representative ERS workshop: The Potential Impact of Climate Variability and Change on Respiratory Disease. Leuven, Belgium, 2008.

---

Research Studies:

• Principle Investigator: Glaxo-Wellcome. Protocol #SLGA 5008. Double-blinded study – Parallel group evaluation of Salmeterol versus placebos in treatment of nocturnal asthma. (July 1994-April 1995)
• Principle Investigator: Glaxo-Wellcome. Protocol #SLGA 5015/5016. Trial to examine the efficacy and safety of Salmeterol Xinofoate 42 mcg bid, BDP 84 mcg qid, and placebo in adolescent and adult subjects with mild to moderate asthma. (August 1995-October 1996)
• Principle Investigator: Schering-Plough. Protocol #P96-233. Study to evaluate clinical and pharmacoeconomic benefits of Vancenase AQ, Ds in allergic rhinitis patients with a history of sinusitis. (September 1996-August 1997)
• Principle Investigator: Schering-Plough Grant. Vocal cord training in asthma. Evaluation of singing and vocal cord technique and exercises on the effect of respiratory function and quality of life. (January 1997-March 1997)
• Principle Investigator: Ortho-McNeil Pharmaceutical. Protocol #CAPSS-043. Multicenter study to evaluate the safety and efficacy of Levofloxacin 500 mg., one daily, in the treatment of community-acquired pneumonia in adults. (February 1999-April 1999)
• Principle Investigator: Glaxo-Wellcome. Protocol #SAS40027. A randomized, double-blind, parallel group, comparative trial of Salmeterol/Fluticasone Propionate Combination Product 50/100 mcg DISKUS inhaler bid versus Fluticasone Propionate 250 mcg DISKUS inhaler bid in adolescents and adults with persistent moderate asthma. (January 2000-2001)
• Principle Investigator: ALA Grant. University of New Hampshire. Central Obesity and Asthma: Possible role of insulin resistance and tumor necrosis factor x. (September 2001-present)
• Principle Investigator: Bentley Pharmaceuticals, University of New Hampshire. Effect of Insulin Nasal Spray Delivery on Fasting Blood Glucose of Healthy Adults. (January 2002-present)
• Principle Investigator: Efficacy of pulmonary rehabilitation in asthma, obstructive sleep apnea, and COPD; a modified once a week program. (2010-present)

---

Publications and Presentations:

• Windt, M., Gasteriger, E., Effect of Supra Lethal Doses of Ionizing Radiation of Sprague-Dawley Rats: Radiation Journal, 1973.
• Windt, M., Asthma, Evolving Therapeutic Regimens, Decision Resources, November 4, 1991.
• Vieira, V. J., Ronan, A.M., Windt, M. R., Tagliaferro, A. R. Elevated atopy in healthy obese women. Am. J. Clin. Nutr. 2005; 82:504-09.
• Tagliaferro, A. R., Windt, M. R., Vieira, V. J., Ronan, A. M. Dietary arachidonic acid and fat mass: Predictors of atopy among asthmatic and non-asthmatic women. Am. J. Clin. Nutr. 2007.
• Tagliaferro, A. R., Windt, M. R., Vieira V. J., Ronan, A. M. Insulin resistance: A predictor of pulmonary function in obese and non-obese asthmatic and non-asthmatic women. Am J. Clin. Nutr. 2009.
• Ayres JG, Forsberg B, Annesi-Maesano I, Dey R, Ebi KL, Helms PJ, Medina-Ramon M, Menne B, Windt M, and Forastiere F, Climate Change and Respiratory Disease: A Position Statement. ERJ Express, February 27, 2009.
• Tagliaferro, A. R., Windt, M. R., Ronan, A. M., Vieira, V. J. Insulin resistance: a risk factor of asthma development in women. Obes. Res. 12(5):PA115, 2004.
• Vieira, V. J., Ronan, A. M., Windt, M.R., Tagliaferro, A.R. Elevated atopy among obese women not related to habitual physical activity. Presented at the 2005 Annual Meeting of the American College of Sports Medicine, June 1-4, Nashville, TN
• Windt, M. R., Tagliaferro, A. R., Ronan, A. M., Vieira, V. J. The positive relationship of atopy to obesity in women is negatively correlated to serum leptin. To be presented at the 2006 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology. March 3-7, Miami Beach, FL.
• Tagliaferro, A. R., Windt, M. R., Ronan, A. M., Vieira, V. J. Obesity, dietary arachidonic acid and risk of allergic disease in women. FASEBJ 20(4):A603, 2006.